Optometrists in Oxford, OH Accepting Medicare

7 Optometrists found. Showing 1 - 7

Dr. Mark Alan Abplanalp, O.D. Optometrist - Corneal and Contact Management Medicare: Medicare Enrolled Practice Location: 5720 College Corner Pike, Oxford, OH 45056 Phone: 513-523-8798    Fax: 513-523-5710

Eye Center Of Oxford Optometrist Medicare: Not Enrolled in Medicare Practice Location: 127 Lynn Ave, Oxford, OH 45056 Phone: 866-788-0001    Fax: 765-966-2975

Dr. Jeffrey Wade Collins, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 127 Lynn Ave, Oxford, OH 45056 Phone: 513-523-6339    Fax: 513-523-6330

Jack B Bridge, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 5225 Morning Sun Rd, Suite B, Oxford, OH 45056 Phone: 513-523-2020    Fax: 513-523-1101

Jack Bridge, O.d., Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5225 Morning Sun Rd, Suite B, Oxford, OH 45056 Phone: 513-523-2020    Fax: 513-523-1101

Myeyedr. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5225 Morning Sun Rd Ste B, Oxford, OH 45056 Phone: 513-523-2020    Fax: 513-523-1101

Family Vision Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 127 Lynn Ave, Oxford, OH 45056 Phone: 513-523-6339    Fax: 513-523-6330

News Archive

Study shows safety, efficacy of endoscopic needle knife therapy for intestinal strictures in IBD patients

Cleveland Clinic doctors have published the first study illustrating the safety and efficacy of endoscopic needle knife therapy for intestinal strictures in patients with inflammatory bowel disorder.

Unity receives first order for new BD Italian Tablet press

Unity Management Group, Inc. is a Health Resource Company specializing in Physician, and Hospital Practice Management, Business Services, Billing Software and Technologies, along with Pharmacy Instrumentation, Calibration, Data Acquisition, and Equipment Distribution.

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

A poor sense of smell increases your risk of dying early, but scientists don't know why

Researchers have found that a poor sense of smell during older age is be associated with an increased likelihood of dying within the next ten years. However, they can't explain why.

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

Read more Medical News

› Verified 6 days ago